Significant breakthroughs in CNS biology, coupled with innovative neuroscience technologies and a more supportive regulatory landscape, have fueled increased investment and pharmaceutical interest in the CNS.
With AbbVie, BMS, and Lundbeck making major acquisitions in the last 12 months alone, this wave of deal-making is redemption for biotech who kept the lights on and are building with greater strength than before.
Join the Neuroscience Innovation Pharma Partnering Summit to:
- Connect with a targeted critical mass of decision-makers aligned with your strategic and scientific goals.
- Build stronger relationships with key pharma and investor contacts to emphasize your company’s competitive edge
- Position your company at the front of scientific innovation to show where you add value
Secure your place here or get in touch with the team – info@hansonwade.com